Open-label, multicenter, effectiveness and safety study of once daily Azilect [Rasagiline] as mono- or adjunct therapy in patients with idiopathic Parkinson's disease.

Trial Profile

Open-label, multicenter, effectiveness and safety study of once daily Azilect [Rasagiline] as mono- or adjunct therapy in patients with idiopathic Parkinson's disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2011

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Teva Neuroscience
  • Most Recent Events

    • 10 Nov 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
    • 30 Jul 2007 Status changed from recruiting to completed.
    • 26 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top